Target

DNA replication enzymes

6 abstracts

Abstract
LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.
Org: Centrum Medyczne Pratia Poznań, Department of Oncology and Hematology, Humanitas University and IRCCS Humanitas Research Hospital, ADC Therapeutics SA, ADC Therapeutics Ltd., ADC Therapeutics America, Inc.,
Abstract
Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multicenter, single-arm, phase 2 trial.
Org: The Central Hospital of Xiao Gan, Xiantao First People’s Hospital, Jianghan Oilfield General Hospital, Xiang Yang Central Hospital, Hubei University of Art and Science,
Abstract
Neoadjuvant serplulimab in combination with concurrent chemoradiotherapy for locally advanced, resectable esophagogastric junction adenocarcinoma.
Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX): An open label, non-comparative phase 1/2 dose escalation and expansion trial.
Org: Institut Cancérologique de l'Ouest, EMR 3738 Université Claude Bernard Lyon 1, Hopital d'instruction des armées de Begin, Lariboisiere Hospital - APHP, Insitut de Cancerologie de L'ouest,
Abstract
The financial toxicity of chemotherapy in Belize.
Org: University of Rochester School of Medicine & Dentistry, Stanford Hospital & Clinics, Saint Louis University School of Medicine, UCSF School of Medicine, Karl Heusner Memorial Hospital,